Update shared on 01 Dec 2025
Analysts have maintained Bio-Techne's price target at $69.17, citing minor adjustments to discount rate and forward P/E assumptions. Overall sentiment and company outlook remain steady.
What's in the News
- Bio-Techne and Nucleai presented pivotal data at the SITC 2025 Annual Meeting. The data demonstrated how AI-driven spatial biology enables more personalized cancer treatments by connecting immune cell interactions within tumors to improved patient outcomes. (Key Developments)
- The company launched the ProximityScope assay in partnership with Leica Biosystems. This launch allows researchers to visualize protein interactions on tissue sections with unprecedented accuracy using the BOND RX platform. (Key Developments)
- Bio-Techne expanded its strategic collaboration with Oxford Nanopore Technologies through 2032. This expansion enables development of additional targeted enrichment sequencing kits for genetic screening and diagnosis. (Key Developments)
- A new distribution agreement with Saguaro Biosciences will leverage Bio-Techne’s global channels to make advanced, non-toxic dyes for cell-based assays available to more researchers worldwide. (Key Developments)
- The company completed its share buyback, repurchasing 2,443,140 shares for $124.06 million under the program announced in May 2025. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target remains unchanged at $69.17 per share.
- Discount Rate has increased slightly from 7.81% to 7.83%.
- Revenue Growth projections are virtually unchanged at 6.40%.
- Net Profit Margin remains steady at approximately 18.74%.
- Future P/E has increased marginally from 47.02x to 47.06x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.